---
title: Single Dose rATG for Renal Allograft Rejection
nct_id: NCT02102854
overall_status: UNKNOWN
phase: PHASE4
sponsor: The Methodist Hospital Research Institute
study_type: INTERVENTIONAL
primary_condition: Acute (Cellular) Renal Allograft Rejection
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02102854.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02102854"
ct_last_update_post_date: 2020-09-03
last_seen_at: "2026-05-12T06:20:56.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Single Dose rATG for Renal Allograft Rejection

**Official Title:** Single Dose rATG for Treatment of Acute Renal Allograft Rejection

**NCT ID:** [NCT02102854](https://clinicaltrials.gov/study/NCT02102854)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** The Methodist Hospital Research Institute
- **Conditions:** Acute (Cellular) Renal Allograft Rejection
- **Start Date:** 2014-03
- **Completion Date:** 2021-10
- **CT.gov Last Update:** 2020-09-03

## Brief Summary

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter.Single large-doses of rATG have been shown to have equivalent safety and efficacy profile compared to the standard daily protocol when used as an induction agent but there are no reported experiences of its use for rejection treatment. Plan to study a single-dose rATG infusion compared to standard rATG administration including correlation to length of hospital stay and hospital costs.

## Detailed Description

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged course is not consistent with the Medicare diagnosis-related group (DRG) for acute rejection which limits rejection admission to 3 days. The prolonged hospitalization results in increased medical costs and uniform financial loss to the hospital for patients admitted under this DRG. In addition there is a patient related toll of the prolonged hospitalization and a potential for additional hospital acquired complications. Single large-doses of rATG have been shown to have equivalent safety and efficacy profile compared to the standard daily protocol when used as an induction agent but there are no reported experiences of its use for rejection treatment. The investigators hypothesize that single-dose rATG infusion will be as safe and efficacious as standard rATG administration when used for rejection treatment and would result in significant reduction in the length of hospital stay (LOS) and hospital costs for rejection treatment.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Male or female subjects aged 18 years or older
2. Experiencing a biopsy-proven acute rejection episode which:

   * will require the use of rATG based on severity, or
   * is exhibiting resistance to corticosteroid treatment, defined as failure of the serum creatinine to decrease after at least 3 days of corticosteroid treatment (≥200 mg/day of methylprednisolone or equivalent)

Exclusion Criteria:

1. Patients with known severe allergy to antithymocyte globulin or rabbits
2. Rejection episode requiring the use of therapeutic plasma exchange immediately subsequent to rATG administration
3. Currently receiving any investigational drug or treatments
```

## Arms

- **Standard dose rATG** (ACTIVE_COMPARATOR) — Standard dose rATG given as daily infusions of 1.5 mg/kg x 4-5 days
- **Single dose rATG** (EXPERIMENTAL) — Single dose rATG give as 2 consecutive 3 mg/kg IV infusions to be completed over a 24-36 hour duration

## Interventions

- **rATG** (DRUG) — Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent \& treat acute rejection in organ transplantation

## Primary Outcomes

- **Hospital length of hospitalization (days)** _(time frame: 7 days)_ — The length of hospitalization for treatment of renal allograft rejection in days will be determined which should be an average of 5-7 days

## Secondary Outcomes

- **Infusion related symptoms** _(time frame: 7 days)_

## Locations (1)

- Houston Methodist Hospital, Houston, Texas, United States — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.houston methodist hospital|houston|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02102854.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02102854*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*